These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16782204)

  • 1. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
    Berlanga C; Flores-Ramos M
    J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
    Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
    McCabe C; Mishor Z; Cowen PJ; Harmer CJ
    Biol Psychiatry; 2010 Mar; 67(5):439-45. PubMed ID: 20034615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.
    Hetzel G; Moeller O; Erfurth A; Michael N; Rothermundt M; Arolt V; Evers S
    Pharmacopsychiatry; 2004 Sep; 37(5):200-5. PubMed ID: 15470798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
    Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G
    Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
    J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
    Andreasen JT; Redrobe JP
    Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A; Bosc M; Polin V
    J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O; Hetzel G; Michael N; Rothermundt M; Arolt V; Erfurth A
    Neuropsychobiology; 2005; 51(2):67-71. PubMed ID: 15741746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram.
    Schmidt C; Leibiger J; Fendt M
    Behav Brain Res; 2016 Jul; 308():205-10. PubMed ID: 27118715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
    Harmer CJ; Shelley NC; Cowen PJ; Goodwin GM
    Am J Psychiatry; 2004 Jul; 161(7):1256-63. PubMed ID: 15229059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
    Crawford AA; Lewis S; Nutt D; Peters TJ; Cowen P; O'Donovan MC; Wiles N; Lewis G
    Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression.
    Linka T; Sartory G; Wiltfang J; Müller BW
    Neurosci Lett; 2009 Sep; 463(1):26-30. PubMed ID: 19616062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression.
    Wagner G; Koch K; Schachtzabel C; Sobanski T; Reichenbach JR; Sauer H; Schlösser RG
    J Psychiatry Neurosci; 2010 Jul; 35(4):247-57. PubMed ID: 20598238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in serotonergic and noradrenergic regulation of human social behaviours.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 Jan; 159(2):216-21. PubMed ID: 11862352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.